APP
AKRO

Alpha Paradigm Partners’s Akero Therapeutics AKRO Stock Holding History

Alpha Paradigm Partners’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$716K Buy
+13,073
New +$560K 0.3% 121

Other funds holding AKRO

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alpha Paradigm Partners's AKRO Position: Q4 2022 in Review

Alpha Paradigm Partners opened a new position in Akero Therapeutics (AKRO) in Q4 2022: 13,073 shares worth $716K. The stake represents 0.3% of the portfolio and ranks #121 among its holdings.

162 funds tracked by Wall St. Rank hold AKRO as of Q4 2022.

  • Alpha Paradigm Partners held 13,073 shares of Akero Therapeutics worth $716K as of Q4 2022.
  • Akero Therapeutics was a new Alpha Paradigm Partners position in Q4 2022.
  • Akero Therapeutics made up 0.3% of Alpha Paradigm Partners's portfolio in Q4 2022, its #121 holding.
  • 162 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.